Timolol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Timolol: From Hypertension and Open-Angle Glaucoma to Primary Hereditary Glaucoma
One-Sentence Summary
Timolol is a beta-blocker originally used for hypertension, open-angle glaucoma and ocular hypertension. The TxGNN model predicts it may be effective for primary hereditary glaucoma (score 98.6%), but there are currently 0 clinical trials and 0 publications supporting this specific prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension, open-angle glaucoma, ocular hypertension (from the knowledge graph, because the Singapore licence records contain no indication text) |
| Predicted New Indication | Primary hereditary glaucoma |
| TxGNN Prediction Score | 98.64% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the compiled data. Based on known pharmacology, timolol is a non-selective beta-adrenergic blocker. In the eye it lowers intraocular pressure (IOP) by reducing aqueous humour production in the ciliary body.
Its efficacy in open-angle glaucoma and ocular hypertension is established. Primary hereditary glaucoma is also a pressure-driven optic neuropathy, so an IOP-lowering drug is mechanistically plausible.
However, the high score is a computational prediction only. It most likely reflects similarity to the already-approved glaucoma indications rather than independent evidence in hereditary forms. No trials or publications were found for this specific condition.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Timolol has 20 valid registrations in Singapore, all ophthalmic solutions or suspensions and none cancelled. Five are shown below. The remaining 15 are mostly fixed-dose combinations with other glaucoma drugs, such as latanoprost, travoprost, bimatoprost, brimonidine, dorzolamide and brinzolamide. Approved indication text is not recorded in the licence data.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| SIN11054P | Timabak Eyedrops 0.5% | Solution | Excelvision |
| SIN08619P | Timoptol-XE Ophthalmic Solution 0.5% | Solution | Santen Pharmaceutical |
| SIN04135P | Timoptol Ophthalmic Solution 0.5% | Solution | Santen Pharmaceutical |
| SIN09709P | Timolol-POS Eye Drops 0.5% | Solution | Ursapharm |
| SIN13744P | Timo-Comod 0.5% Eye Drops | Solution | Ursapharm |
Safety Considerations
- Conditions flagged in the knowledge graph as contraindications (not label text): orthostatic hypotension, anxiety and neurotic disorders, kidney disease, liver disease, pancreatitis, gallbladder disease, systemic lupus erythematosus, diabetes mellitus and diabetic ketoacidosis, gout, hypercalcaemia, myasthenia gravis and other neuromuscular junction disorders, among others.
- Drug Interactions: 100 interactions are recorded.
- Major: epinephrine.
- Moderate: corticosteroids (hydrocortisone, dexamethasone, betamethasone, budesonide, triamcinolone), anticholinergics (atropine, hyoscyamine, dicyclomine), bupropion, morphine, cimetidine, canagliflozin, dapagliflozin, chlorpropamide, lorcaserin, and calcium salts.
- Minor: acetylsalicylic acid and magnesium oxide.
- Standard beta-blocker precautions apply even with topical use, because of systemic absorption. These cover asthma/COPD, bradycardia, heart block and heart failure. The literature also includes a case report of timolol eye drops associated with interstitial lung disease.
Please refer to the package insert for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on the model score alone, with no trials or literature for primary hereditary glaucoma. The score likely reflects similarity to timolol's existing glaucoma indications. Timolol is already marketed in Singapore for glaucoma, so this prediction adds little beyond the current use.
To proceed, the following is needed:
- Clinical or observational evidence of timolol's IOP-lowering effect in hereditary or developmental glaucoma, including paediatric safety data
- Detailed mechanism of action data
- HSA package insert warnings and contraindications
- Confirmation of approved indication wording for the Singapore licences
Note: The second-ranked prediction, closed-angle glaucoma (score 97.2%), has stronger support: several randomised comparisons of timolol versus latanoprost in chronic angle-closure glaucoma, plus meta-analyses (evidence level L2). It may be a better candidate for further research. Timolol would be an adjunct to procedures that open the angle, not a standalone treatment.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.